Sybleu Past Earnings Performance
Past criteria checks 0/6
Sybleu's earnings have been declining at an average annual rate of -25.4%, while the Pharmaceuticals industry saw earnings declining at 0.3% annually. Revenues have been declining at an average rate of 0.02% per year.
Key information
-25.4%
Earnings growth rate
-243.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -0.02% |
| Return on equity | n/a |
| Net Margin | -2,632.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Sybleu makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | 0 | 0 | 0 |
| 30 Sep 23 | 0 | 0 | 0 | 0 |
| 30 Jun 23 | 0 | 0 | 0 | 0 |
| 31 Mar 23 | 0 | 0 | 0 | 0 |
| 31 Dec 22 | 0 | 0 | 0 | 0 |
| 30 Sep 22 | 0 | 0 | 0 | 0 |
| 30 Jun 22 | 0 | 0 | 0 | 0 |
| 31 Mar 22 | 0 | 0 | 0 | 0 |
| 31 Dec 21 | 0 | 0 | 0 | 0 |
| 30 Sep 21 | 0 | 0 | 0 | 0 |
| 30 Jun 21 | 0 | 0 | 0 | 0 |
Quality Earnings: SYBE is currently unprofitable.
Growing Profit Margin: SYBE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SYBE is unprofitable, and losses have increased over the past 5 years at a rate of 25.4% per year.
Accelerating Growth: Unable to compare SYBE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SYBE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13%).
Return on Equity
High ROE: SYBE's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.